SecBot SecBot

GWLL

GOLDENWELL BIOTECH, INC.
OTC· Food and Kindred Products· Inc. NV· CIK 0001800373 Consumer & Retail
$0.6500 +0.00 (+0.00%)
Oct 23 4:00 PM ET · prev $0.6500
1 year
−56.7%
from $1.50 · Oct 27
30 days
−5.8%
from $0.6897
52-week range
$0.5100–7.00
−91% from high · low May 20
Avg volume 20D
37
Oct 19 spike 502
Short interest
16
0.0%
Days to cover
1.0
at average volume
Filing reports
7
analyzed by SecBot
SecBot read BEARISH 4 reports · 90 days
Balance 2 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 3/4
Strongest BEARISH Goldenwell Biotech appointed Ming Zhou as a director on October 8, 2026, expanding the board to four…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • Short sellersSTEADY

    Short interest 0.0% to 16 shares. 1.0 days to cover.

  • TrendDOWNTREND

    6% below its 50-day average.

Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 9, 2026 SEC
Ming Zhou filed a Schedule 13D disclosing beneficial ownership of 20,000,000 shares (20.2%) of Goldenwell Biotech…
SC 13D — Impact 4/10
Oct 9, 2026 SEC
Ming Zhou filed a Form 3 initial statement of beneficial ownership, reporting 20,000,000 shares of common stock in…
3 — Impact 2/10
Oct 9, 2026 SEC
Goldenwell Biotech appointed Ming Zhou as a director on October 8, 2026, expanding the board to four members. In…
8-K — Impact 7/10
Sep 10, 2026 Earnings calendar
GWLL Q2 2026 Earnings Scheduled — 2026-09-10
Jun 2, 2026 Event
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate
WARNING: ABUSE, MISUSE, and ADDICTION Dextroamphetamine saccharate, amphetamine aspartate monohydrat

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· May 15, 2026
16
shares short
0.0%
vs prior settlement
1.0
days to cover
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 10, 2026
Earnings date
GWLL Q2 2026 Earnings Scheduled — 2026-09-10
Jun 29, 2026
Earnings date
GWLL Q1 2026 Earnings Scheduled — 2026-06-29
Jun 2, 2026
FDA
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate
WARNING: ABUSE, MISUSE, and ADDICTION Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfa
May 26, 2026
Earnings date
GWLL Q1 2026 Earnings Scheduled — 2026-05-26
May 15, 2026
Earnings date
GWLL Q4 2025 Earnings Scheduled — 2026-05-15

SecBot reports

7 filings · 0 bullish · 5 bearish · 2 neutral
All GWLL filing & press-release reports (7)